Research
Amla
13 peer-reviewed studies curated from PubMed and Semantic Scholar.
Studies
Sorted by quality and recency
The impact of Emblica Officinalis (Amla) on lipid profile, glucose, and C-reactive protein: A systematic review and meta-analysis of randomized controlled trials.
Systematic review and meta-analysis of RCTs examining the effects of Amla supplementation on lipid profile, glucose, and C-reactive protein concentrations in adults. Amla supplementation significantly reduced CRP, fasting blood glucose, LDL-c, total cholesterol, and serum triglyceride concentrations, and increased HDL-c.
Potential effect of tropical fruits Phyllanthus emblica L. for the prevention and management of type 2 diabetic complications: a systematic review of recent advances.
Systematic review of recent advances on Phyllanthus emblica for the prevention and management of type 2 diabetic complications. The review discusses its potential mechanisms, including enhancing insulin function, reducing insulin resistance, and alleviating inflammatory reactions.
AMBER trial (amla-based extract for endobronchial ultrasound cough reduction): A randomized controlled study.
RCT comparing the efficacy of Emblica officinalis (Amla) extract, dextromethorphan, and their combination for cough suppression in 118 patients undergoing endobronchial ultrasound. E. officinalis significantly reduced cough with efficacy comparable to dextromethorphan and showed an excellent safety profile.
The effect of an oral product containing Amla fruit (Phyllanthus emblica L.) on female androgenetic alopecia: A randomized controlled trial.
This triple-blind, randomized controlled trial investigated the effect of an oral product containing Amla fruit on Female Androgenetic Alopecia (FAGA) in 60 women. The intervention group received Amla syrup, which significantly increased the anagen-to-telogen ratio and satisfaction compared to placebo, with no remarkable side effects.
The effects of add-on therapy of Phyllanthus Emblica (Amla) on laboratory confirmed COVID-19 Cases: A randomized, double-blind, controlled trial.
This RCT evaluated the effect of Phyllanthus Emblica (Amla) as an add-on therapy in 61 COVID-19 patients. The intervention group had a significantly shorter length of stay in the hospital and showed improvements in oxygen saturation, lung involvement, and C-reactive protein levels compared to the control group. However, RT-PCR results were not significantly different between the groups.
Antihypertensive and pleiotropic effects of Phyllanthus emblica extract as an add-on therapy in patients with essential hypertension-A randomized double-blind placebo-controlled trial.
RCT of 150 patients with essential hypertension testing Phyllanthus emblica extract (500 mg) vs placebo for 12 weeks. Phyllanthus emblica showed no additional reduction in blood pressure or improvement in oxidant status, antioxidant capacity, lipid profile, HbA1C, arterial stiffness, or hs-CRP levels.
Effect of Amla Extract on Body Mass Index, Waist Circumference, Total Body Fat, Visceral Fat, Skeletal Muscle Mass, Body Age, and Related Parameters: A Randomized, Open-Label Clinical Study in Obese Participants.
This randomized, open-label clinical study assessed the efficacy of amla extract AMX-160 in 40 obese participants. Supplementation with 1 g of AMX-160 significantly reduced visceral fat, increased skeletal muscle mass, decreased subcutaneous fat, and improved various anthropometric parameters and lipid profiles.
Antibacterial and anti-inflammatory effects of a novel herb-mediated nanocomposite mouthwash in plaque-induced gingivitis: A randomized controlled trial.
Double-blind RCT of 30 gingivitis patients comparing an amla seed-mediated GO-Ag nanocomposite mouthwash to 0.2% chlorhexidine mouthwash. The amla mouthwash significantly reduced plaque, gingival inflammation, and CFUs, but was not equivalent to the CHX mouthwash.
A randomized, double blind, placebo controlled, multicenter clinical trial to assess the efficacy and safety of Emblica officinalis extract in patients with dyslipidemia.
A randomized, double-blind, placebo-controlled trial assessed the efficacy of amla (Emblica officinalis) extract in 98 dyslipidemic patients. Amla extract significantly reduced total cholesterol, triglycerides, LDL-C, and VLDL-C levels compared to placebo, and improved lipid ratios and atherogenic index of the plasma. The study suggests amla extract has potential as a treatment for dyslipidemia without reducing CoQ10 levels.
Efficacy and safety of Amla (Phyllanthus emblica L.) in non-erosive reflux disease: a double-blind, randomized, placebo-controlled clinical trial.
This double-blind, randomized, placebo-controlled clinical trial evaluated the efficacy and safety of Amla tablets in 68 patients with non-erosive reflux disease (NERD). The study found that Amla significantly reduced the frequency and severity of heartburn and regurgitation compared to placebo.
Effect of Amla fruit (Emblica officinalis Gaertn.) on blood glucose and lipid profile of normal subjects and type 2 diabetic patients.
The study evaluated the anti-hyperglycemic and lipid-lowering properties of Emblica officinalis fruit in normal and diabetic human volunteers. Significant decreases in fasting and 2-h post-prandial blood glucose levels, total cholesterol, triglycerides, and improvements in HDL and LDL cholesterol levels were observed after 21 days of supplementation.
Effect of Subgingivally Delivered 10% Emblica officinalis Gel as an Adjunct to Scaling and Root Planing in the Treatment of Chronic Periodontitis - A Randomized Placebo-controlled Clinical Trial.
RCT investigating the effect of subgingival application of 10% Emblica officinalis gel as an adjunct to scaling and root planing in chronic periodontitis. The test group showed significantly more reduction in periodontal parameters compared to the control group at 2 and 3 months post-therapy.
PROTECTIVE EFFECTS OF PHYLLANTHUS EMBLICA LEAF EXTRACT ON SODIUM ARSENITE-MEDIATED ADVERSE EFFECTS IN MICE
Animal study evaluating the protective effects of Phyllanthus emblica leaf extract (PLE) on arsenic-mediated toxicity in mice. PLE supplementation prevented weight loss and minimized organ enlargement caused by arsenic exposure, though it did not significantly reduce arsenic deposition in tissues.